This study evaluates the effect of photobiomodulation (PBM) therapy using a MLS® class IV laser on chronic pain and fatigue in patients with hypermobile Ehlers-Danlos Syndrome (hEDS). hEDS is a hereditary connective tissue disorder characterized by joint hypermobility, chronic pain, and debilitating fatigue, for which therapeutic options remain limited.
Participants will receive 10 PBM sessions over 5 weeks (2 sessions per week), using red and near-infrared light (808 nm continuous + 905 nm pulsed) applied to painful areas identified at baseline. Pain (Visual Analogue Scale), multidimensional fatigue (MFI-20), and quality of life (EQ-5D-5L) will be assessed at baseline (T0), end of treatment (week 5), and follow-up (week 10).
This is a pilot observational study - the first to document the effect of MLS® laser PBM in hEDS. No additional procedures beyond routine care are required.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Age ≥ 18 years
* Confirmed diagnosis of hypermobile Ehlers-Danlos Syndrome (hEDS) according to 2017 International Consortium criteria
* Chronic pain ≥ 3 months, average VAS score ≥ 4/10 over the preceding week
* Stable analgesic treatment for ≥ 4 weeks (if any)
* Follow-up at Centre Médical ISM, Boulogne-Billancourt
* Informed and non-opposition signed
Exclusion Criteria:
* Suspicious or malignant skin lesion on areas to be treated
* Non-modifiable photosensitizing treatment
* Pregnancy or breastfeeding
* Photosensitive epilepsy
* Acute articular inflammatory flare at inclusion date
* Analgesic treatment modification within 4 weeks prior to inclusion
* Simultaneous participation in another research protocol
Primary outcome measure(s)
Change in chronic pain intensity — Baseline (T0) to Week 5 (end of PBM treatment cycle) Change in pain intensity measured by the Visual Analogue Scale (VAS, 0-10), representing average pain over the preceding week. A decrease of ≥ 1.5 points is considered clinically meaningful.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
